AUS
NZ
UK
CA
USA
IND
Highlights
Lumos Diagnostics signs exclusive multi-year US distribution deal with PHASE Scientific
Agreement includes milestone payments tied to regulatory progress for FebriDx®
CLIA waiver study nearing completion with submission expected in coming weeks
Lumos Diagnostics Holdings Ltd (ASX:LDX), a healthcare diagnostics company listed on the All Ordinaries, has announced a significant commercial agreement with PHASE Scientific. The multi-year exclusive US distribution contract centres on Lumos' rapid diagnostic device FebriDx®, pending regulatory clearance under the Clinical Laboratory Improvement Amendments (CLIA) waiver process by the US Food and Drug Administration.
The agreement marks one of the largest known deals for an ASX-listed point-of-care diagnostics firm and underscores Lumos' ambitions in the international healthcare market.
Distribution Terms Include Tiered Milestone Payments and Volume Commitments
Under the structure of the six-year agreement, PHASE Scientific has secured exclusive US distribution rights for FebriDx®. The deal is underpinned by multiple financial milestones linked to regulatory approvals and order volumes. An initial commitment has already been made, with further payments contingent on FDA application submissions and the eventual granting of a CLIA waiver.
In the event that CLIA clearance is not granted, the agreement contains a revised delivery model with adjusted minimum order volumes and an alternate valuation framework.
Lumos will maintain ownership of all FebriDx® intellectual property and retain manufacturing responsibilities throughout the contract term.
FebriDx® Positioned Within PHASE Scientific’s INDICAID® Brand Network
The FebriDx® test will be integrated into PHASE Scientific’s INDICAID® suite of rapid diagnostic products. This brand has already been widely distributed across several global markets. PHASE’s operational footprint in the United States, which includes urgent care clinics and diagnostics networks, is expected to support broad accessibility for FebriDx® once regulatory steps are cleared.
Leadership from both companies highlighted the alignment between Lumos’ technology and PHASE Scientific’s commercial strategy. PHASE views FebriDx® as a complementary addition to its respiratory diagnostic portfolio.
Regulatory Milestone Nears as CLIA Study Wraps Up
Lumos has reported that its clinical study required for CLIA waiver approval is close to completion. The study is designed to demonstrate FebriDx®’s effectiveness in simple-care environments such as physician offices and urgent care centres across the US.
Final enrolment of patients is expected imminently, with the application submission to the FDA scheduled shortly thereafter. Upon completion of enrolment, Lumos will also trigger a milestone payment from its federal partner, the Biomedical Advanced Research and Development Authority (BARDA).
Strategic Pathway Beyond FebriDx® Remains Active
Lumos has reiterated its broader roadmap to expand its diagnostic test offerings. The company continues to work on new technologies and deepen commercial collaborations across additional markets and partners.
While Lumos has acknowledged ongoing financing conversations, the company has indicated these discussions are in early stages and not yet ready for public disclosure.
